Fig. 1
Schematic design of the experimental protocol. A, B EAElow mice were C57BL/6J mice s.c. induced by immunization with 200 µg of MOG35–55 and 300 µg of Mtb (A), while EAEhigh mice were induced with 200 µg of MOG peptide and 500 µg of Mtb (B). LPAR1–3 antagonist (A) or agonist (B) was i.p. injected once daily from onset phase (day 8–9 after EAE induction) of motor disability. Level of motor disability was then measured daily until the last day of the experiment. For various analyses, mice were euthanized at the peak phase (day 19–20 after EAE induction) of neurological symptoms